Lenacapavir

Lenacapavir, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. After initiation, lenacapavir is administered by subcutaneous injection every 6 months.

ARV U.S. Brand Name
Sunlenca
ARV Abbreviation(s)
LEN
U.S. FDA Label
Label
ARV Class
Capsid inhibitors
First U.S. Approval
U.S. Manufacturer
Sunlenca website for US healthcare professionals (Gilead Sciences)
Formulations
Strength Formulation Description Boosted
300 mg
Film-Coated Tablets
beige oval tablet
No
463.5 mg in 1.5 mL single dose vial
Subcutaneous Injection
Yellow liquid
No
Generic Available?
No
Other Reference Links
National HIV Curriculum
U.S. Guidelines Links
Lenacapavir information for patients
Adult dosing
2 x 300 mg tablets on days 1 and 2 during initiation phase only. If choosing initiation option 2, add 1 300 mg tablet on day 8. Film-Coated Tablets  
2 x 1.5 mL injections. For initiation option 1, taken on day 1 and then every 6 months. For regimen option 2, taken on day 15 and then every 6 months. Subcutaneous Injection

See package insert for regimen initiation options and details.

Pediatric dosing
       
Assistance Programs
Gilead Advancing Access program
Displaying 101 - 106 of 106
Interaction Color Code Clinical Bottom Line Clinical Effects Drug 1 effect Drug 2 dose Drug 2 effect Management
Lenacapavir Amlodipine Yellow: Adjust dosing Minimal data to guide interaction: weigh risks and benefits of using this combination

Potential increased risk of amlodipine adverse effects

If coadministering, monitor for cardiac medication adverse effects (e.g. hypotension)
Lenacapavir Amiodarone Red: Avoid combination Do not coadminister: potentially increased levels of amiodarone

Potential increased risk of amiodarone and lenacapavir adverse effects

Use alternative agents.
Lenacapavir Alprazolam Yellow: Adjust dosing Minimal data to guide interaction: weigh risks and benefits of using this combination

Potential increased risk of sedation, respiratory depression

If coadministering, use lowest effective dose and monitor for alprazolam adverse effects
Lencapavir Alfuzosin Yellow: Adjust dosing Minimal data to guide interaction: weigh risks and benefits of using this combination

Potential for increased alfuzosin effects

Consider alternative to alfuzosin. If coadministered, monitor for adverse effects (e.g. hypotension)
Lenacapavir Rifampin Red: Avoid combination Do not coadminister: decreased levels of lenacapavir

Potential decrease in antiretroviral efficacy

AUC decreased 84%; Cmax decreased 55%

 600 mg daily (fasted)

Not reported

Use alternative agents
Lenacapavir
Subscribe to Lenacapavir